Coherus Biosciences (CHRS) PT Lowered to $27 at Citi
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 +5.26%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citi analyst Mohit Bansal lowered the price target on Coherus Biosciences (NASDAQ: CHRS) to $27.00 (from $30.00) while maintaining a Buy rating.
You May Also Be Interested In
- Berenberg Upgrades Accelleron Industries AG (ACLN:SW) to Buy
- TUI AG (TUI1:GR) (TUIFY) PT Lowered to EUR7.20 at Citi
- Costain Group PLC (COST:LN) PT Raised to GBP2.75 at Berenberg
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
